Albert Ludolph
Department of Neurology, University of Ulm, Germany
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Albert Ludolph as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:47 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT03127267 · Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS PatientsAB Science · recruiting · Amyotrophic Lateral Sclerosis · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:47 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:47 UTC. The ranking covers the 200 most relevant of 45 PubMed records, and a shared surname and initials can bring in a namesake. All 45 on PubMed
- Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS.N Engl J Med · 2022807 citationsRCR 65.6
- Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS.N Engl J Med · 2020475 citationsRCR 23.5
- Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer's disease: a phase 1b, randomized, placebo-controlled trial.Nat Med · 2023276 citationsRCR 27.8
- Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.Brain · 2009253 citationsRCR 7.5
- Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial.Lancet Neurol · 2014246 citationsRCR 8.4
- Cognitive impairment in patients with multiple system atrophy and progressive supranuclear palsy.Brain · 2010226 citationsRCR 7.6
- Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial.Lancet Neurol · 2013198 citationsRCR 6.5
- High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind study.J Neural Transm (Vienna) · 2005162 citationsRCR 4.1
- Safety and Effectiveness of Long-term Intravenous Administration of Edaravone for Treatment of Patients With Amyotrophic Lateral Sclerosis.JAMA Neurol · 2022160 citationsRCR 13.7
- 140 citationsRCR 7.7